Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_3
1
25%
Ph phase_4
1
25%
Ph phase_2
1
25%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(2)
Other(1)

Detailed Status

Terminated2
Completed1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
33.3%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)

Trials by Status

terminated250%
completed125%
unknown125%

Recent Activity

0 active trials
Showing 4 of 4
unknownphase_4

High Dose Methylprednisolone Verses Low Dose in Correction of Congenital Acynotic Heart Disease

NCT05103397
completedphase_1

Traumatic Optic Neuropathy Treatment Trial (TONTT)

NCT01783847
terminatedphase_3

Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis

NCT01773616
terminatedphase_2

Plasma Exchange for Renal Vasculitis

NCT01408836

Clinical Trials (4)

Showing 4 of 4 trials
NCT05103397Phase 4

High Dose Methylprednisolone Verses Low Dose in Correction of Congenital Acynotic Heart Disease

Unknown
NCT01783847Phase 1

Traumatic Optic Neuropathy Treatment Trial (TONTT)

Completed
NCT01773616Phase 3

Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis

Terminated
NCT01408836Phase 2

Plasma Exchange for Renal Vasculitis

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4